Company intelligence / Profile preview

Groupe Magellan

Tampa, Florida, USAgroupe-magellan.com ↗

Ownership: Private
Development stage: Other

Overview

Magellan BioScience Group develops proprietary media to culture marine microbes and offers large research libraries of unique microbial-derived compounds. The company specializes in providing these resources for early-stage drug discovery efforts targeting novel chemical entities. It has over 10,000 microbial strains in its collection and offers both natural product extracts and synthetic peptide libraries. No clinical results or advanced development programs are reported.

Modalities: Natural productsSynthetic peptides
Industry: Drug Discovery Services

Partnerships

Sirona Biochem Corp.

Beyond the preview

Go deeper on Groupe Magellan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Groupe Magellan.

Explore the full profile